The production of several viral vaccines depends on chicken embryo fibroblasts or embryonated chicken eggs. To replace this logistically demanding substrate, we created continuous anatine suspension cell lines (CR and CR.pIX), developed chemically-defined media, and established production processes for different vaccine viruses. One of the processes investigated in greater detail was developed for modified vaccinia virus Ankara (MVA). MVA is highly attenuated for human recipients and an efficient vector for reactogenic expression of foreign genes. Because direct cell-to-cell spread is one important mechanism for vaccinia virus replication, cultivation of MVA in bioreactors is facilitated if cell aggregates are induced after infection. This dependency may be the mechanism behind our observation that a novel viral genotype (MVA-CR) accumulates with serial passage in suspension cultures. Sequencing of a major part of the genomic DNA of the new strain revealed point mutations in three genes. We hypothesize that these changes confer an advantage because they may allow a greater fraction of MVA-CR viruses to escape the host cells for infection of distant targets. Production and purification of MVA-based vaccines may be simplified by this combination of designed avian cell line, chemically defined media and the novel virus strain.
References
[1]
Ehreth, J. The value of vaccination: A global perspective. Vaccine 2003, 21, 4105–4117, doi:10.1016/S0264-410X(03)00377-3.
Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380, 2095–2128, doi:10.1016/S0140-6736(12)61728-0.
[4]
Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.; et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209–2220, doi:10.1056/NEJMoa0908492.
Kemper, A.R.; Davis, M.M.; Freed, G.L. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 2002, 5, 84–90.
[9]
Radosevi？, K.; Rodriguez, A.; Lemckert, A.; Goudsmit, J. Heterologous prime-boost vaccinations for poverty-related diseases: Advantages and future prospects. Expert Rev. Vaccines 2009, 8, 577–592, doi:10.1586/erv.09.14.
[10]
Nascimento, I.P.; Leite, L.C. Recombinant vaccines and the development of new vaccine strategies. Braz. J. Med. Biol. Res. 2012, 45, 1102–1111, doi:10.1590/S0100-879X2012007500142.
Cottingham, M.G.; van Maurik, A.; Zago, M.; Newton, A.T.; Anderson, R.J.; Howard, M.K.; Schneider, J.; Skinner, M.A. Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies. Clin. Vaccine Immunol. 2006, 13, 747–757, doi:10.1128/CVI.00088-06.
[13]
Lin, S.-W.; Hensley, S.E.; Tatsis, N.; Lasaro, M.O.; Ertl, H.C. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J. Clin. Invest. 2007, 117, 3958–3970.
[14]
Robert-Guroff, M. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 2007, 18, 546–556, doi:10.1016/j.copbio.2007.10.010.
[15]
Hodge, J.W.; Schlom, J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res. 1999, 59, 5106–5111.
[16]
Coutant, F.; Frenkiel, M.-P.; Despres, P.; Charneau, P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 2008, 3, e3973.
[17]
Cyrklaff, M.; Risco, C.; Fernández, J.J.; Jiménez, M.V.; Estéban, M.; Baumeister, W.; Carrascosa, J.L. Cryo-electron tomography of vaccinia virus. Proc. Natl. Acad. Sci. USA 2005, 102, 2772–2777, doi:10.1073/pnas.0409825102.
[18]
Arif, B.M. Recent advances in the molecular biology of entomopoxviruses. J. Gen. Virol. 1995, 76, 1–13, doi:10.1099/0022-1317-76-1-1.
[19]
Gubser, C.; Hué, S.; Kellam, P.; Smith, G.L. Poxvirus genomes: A phylogenetic analysis. J. Gen. Virol. 2004, 85, 105–117, doi:10.1099/vir.0.19565-0.
[20]
Li, G.; Chen, N.; Feng, Z.; Buller, R.M.L.; Osborne, J.; Harms, T.; Damon, I.; Upton, C.; Esteban, D.J. Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication. Virol. J. 2006, 3, doi:10.1186/1743-442X-3-88.
[21]
Meisinger-Henschel, C.; Schmidt, M.; Lukassen, S.; Linke, B.; Krause, L.; Konietzny, S.; Goesmann, A.; Howley, P.; Chaplin, P.; Suter, M.; et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J. Gen. Virol. 2007, 88, 3249–3259.
[22]
Thézé, J.; Takatsuka, J.; Li, Z.; Gallais, J.; Doucet, D.; Arif, B.; Nakai, M.; Herniou, E.A. New insights into the evolution of Entomopoxvirinae from the complete genome sequences of four entomopoxviruses infecting Adoxophyes honmai, Choristoneura biennis, Choristoneura rosaceana, and Mythimna separa. J. Virol. 2013, 87, 7992–8003, doi:10.1128/JVI.00453-13.
[23]
Jin, X.; Ramanathan, M., Jr.; Barsoum, S.; Deschenes, G.R.; Ba, L.; Binley, J.; Schiller, D.; Bauer, D.E.; Chen, D.C.; Hurley, A.; et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J. Virol. 2002, 76, 2206–2216, doi:10.1128/jvi.76.5.2206-2216.2002.
[24]
Cebere, I.; Dorrell, L.; McShane, H.; Simmons, A.; McCormack, S.; Schmidt, C.; Smith, C.; Brooks, M.; Roberts, J.E.; Darwin, S.C.; et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006, 24, 417–425, doi:10.1016/j.vaccine.2005.08.041.
[25]
Vuola, J.M.; Keating, S.; Webster, D.P.; Berthoud, T.; Dunachie, S.; Gilbert, S.C.; Hill, A.V. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 2005, 174, 449–455.
[26]
Webster, D.P.; Dunachie, S.; Vuola, J.M.; Berthoud, T.; Keating, S.; Laidlaw, S.M.; McConkey, S.J.; Poulton, I.; Andrews, L.; Andersen, R.F.; et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. USA 2005, 102, 4836–4841, doi:10.1073/pnas.0406381102.
[27]
McShane, H.; Behboudi, S.; Goonetilleke, N.; Brookes, R.; Hill, A.V. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8+- and CD4+-T-cell epitopes from antigen 85A. Infect. Immun. 2002, 70, 1623–1626, doi:10.1128/IAI.70.3.1623-1626.2002.
[28]
Kantoff, P.W.; Schuetz, T.J.; Blumenstein, B.A.; Glode, L.M.; Bilhartz, D.L.; Wyand, M.; Manson, K.; Panicali, D.L.; Laus, R.; Schlom, J.; et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2010, 28, 1099–1105, doi:10.1200/JCO.2009.25.0597.
[29]
Dangoor, A.; Lorigan, P.; Keilholz, U.; Schadendorf, D.; Harris, A.; Ottensmeier, C.; Smyth, J.; Hoffmann, K.; Anderson, R.; Cripps, M.; et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol. Immunother. 2010, 59, 863–873, doi:10.1007/s00262-009-0811-7.
[30]
Mayr, A.; Hochstein-Mintzel, V; Stickl, H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 1975, 3, 6–14. (in German), doi:10.1007/BF01641272.
[31]
Mayr, A.; Munz, E. Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralbl Bakteriol Orig. 1964, 195, 24–35. (in German).
[32]
Meyer, H.; Sutter, G.; Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72, 1031–1038, doi:10.1099/0022-1317-72-5-1031.
[33]
Carroll, M.W.; Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238, 198–211, doi:10.1006/viro.1997.8845.
[34]
Blanchard, T.J.; Alcami, A.; Andrea, P.; Smith, G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. J. Gen. Virol. 1998, 79, 1159–1167.
[35]
Drexler, I.; Heller, K.; Wahren, B.; Erfle, V.; Sutter, G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 1998, 79, 347–352.
[36]
Sutter, G.; Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 1992, 89, 10847–10851, doi:10.1073/pnas.89.22.10847.
[37]
Sutter, G.; Wyatt, L.S.; Foley, P.L.; Bennink, J.R.; Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12, 1032–1040, doi:10.1016/0264-410X(94)90341-7.
[38]
Drillien, R.; Spehner, D.; Hanau, D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 2004, 85, 2167–2175, doi:10.1099/vir.0.79998-0.
[39]
Liu, L.; Chavan, R.; Feinberg, M.B. Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 2008, 9, 15, doi:10.1186/1471-2172-9-15.
Kremer, M.; Volz, A.; Kreijtz, J.H.C.M.; Fux, R.; Lehmann, M.H.; Sutter, G. Easy and Efficient Protocols for Working with Recombinant Vaccinia Virus MVA. In Vaccinia Virus and Poxvirology; Humana Press: New York, NY, USA, 2012; pp. 59–92.
[42]
Smith, G.L.; Moss, B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 1983, 25, 21–28, doi:10.1016/0378-1119(83)90163-4.
[43]
Stickl, H.; Hochstein-Mintzel, V.; Mayr, A.; Huber, H.C.; Sch？fer, H.; Holzner, A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author’s transl). Dtsch. Med. Wochenschr. 1974, 99, 2386–2392. (in German), doi:10.1055/s-0028-1108143.
[44]
Mayr, A. Smallpox vaccination and bioterrorism with pox viruses. Comp. Immunol. Microbiol. Infect. Dis. 2003, 26, 423–430, doi:10.1016/S0147-9571(03)00025-0.
[45]
Coulibaly, S.; Brühl, P.; Mayrhofer, J.; Schmid, K.; Gerencer, M.; Falkner, F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005, 341, 91–101, doi:10.1016/j.virol.2005.06.043.
[46]
Cox, H.R. Active immunization against poliomyelitis. Bull. N. Y. Acad. Med. 1953, 29, 943–960.
[47]
Hess, R.D.; Weber, F.; Watson, K.; Schmitt, S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 2012, 30, 2715–2727, doi:10.1016/j.vaccine.2012.02.015.
[48]
Jacobs, J.P.; Jones, C.M.; Baille, J.P. Characteristics of a human diploid cell designated MRC-5. Nature 1970, 227, 168–170, doi:10.1038/227168a0.
[49]
Enserink, M. Influenza. Crisis underscores fragility of vaccine production system. Science 2004, 306, 385, doi:10.1126/science.306.5695.385.
[50]
Uscher-Pines, L.; Barnett, D.J.; Sapsin, J.W.; Bishai, D.M.; Balicer, R.D. A systematic analysis of influenza vaccine shortage policies. Public Health 2008, 122, 183–191, doi:10.1016/j.puhe.2007.06.005.
[51]
Jordan, I.; Vos, A.; Beilfuss, S.; Neubert, A.; Breul, S.; Sandig, V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27, 748–756, doi:10.1016/j.vaccine.2008.11.066.
[52]
B？ni, J.; Stalder, J.; Reigel, F.; Schüpbach, J. Detectionof reverse transcriptase activity in live attenuated virus vaccines. Clin. Diagn. Virol. 1996, 5, 43–53, doi:10.1016/0928-0197(95)00159-X.
[53]
Weissmahr, R.N.; Schüpbach, J.; B？ni, J. Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J. Virol. 1997, 71, 3005–3012.
[54]
Herniou, E.; Martin, J.; Miller, K.; Cook, J.; Wilkinson, M.; Tristem, M. Retroviral diversity and distribution in vertebrates. J. Virol. 1998, 72, 5955–5966.
[55]
Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; et al. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860–921, doi:10.1038/35057062.
[56]
Belshaw, R.; Pereira, V.; Katzourakis, A.; Talbot, G.; Paces, J.; Burt, A.; Tristem, M. Long-term reinfection of the human genome by endogenous retroviruses. Proc. Natl. Acad. Sci. USA 2004, 101, 4894–4899.
[57]
Huda, A.; Polavarapu, N.; Jordan, I.K.; McDonald, J.F. Endogenous retroviruses of the chicken genome. Biol. Direct 2008, 3, 9, doi:10.1186/1745-6150-3-9.
[58]
Huang, Y.; Li, Y.; Burt, D.W.; Chen, H.; Zhang, Y.; Qian, W.; Kim, H.; Gan, S.; Zhao, Y.; Li, J.; et al. The duck genome and transcriptome provide insight into an avian influenza virus reservoir species. Nat. Genet. 2013, 45, 776–783, doi:10.1038/ng.2657.
Payne, L.N.; Howes, K.; Gillespie, A.M.; Smith, L.M. Host range of Rous sarcoma virus pseudotype RSV(HPRS-103) in 12 avian species: Support for a new avian retrovirus envelope subgroup, designated J. J. Gen. Virol. 1992, 73, 2995–2997, doi:10.1099/0022-1317-73-11-2995.
[61]
Shoyab, M.; Baluda, M.A. Homology between avian oncornavirus RNAs and DNA from several avian species. J. Virol. 1975, 16, 1492–1502.
[62]
Philipp, H.-C.; Kolla, I. Laboratory host systems for extraneous agent testing in avian live virus vaccines: Problems encountered. Biol. J. Int. Assoc. Biol. Stand. 2010, 38, 350–351.
[63]
Grachev, V.; Magrath, D.; Griffiths, E. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirements for biological susbstances no. 50). Biol. J. Int. Assoc. Biol. Stand. 1998, 26, 175–193.
[64]
Yang, H.; Zhang, L.; Galinski, M. A probabilistic model for risk assessment of residual host cell DNA in biological products. Vaccine 2010, 28, 3308–3311, doi:10.1016/j.vaccine.2010.02.099.
[65]
Wierenga, D.E.; Cogan, J.; Petricciani, J.C. Administration of tumor cell chromatin to immunosuppressed and non-immunosuppressed non-human primates. Biologicals 1995, 23, 221–224, doi:10.1006/biol.1995.0036.
[66]
Jordan, I.; Northoff, S.; Thiele, M.; Hartmann, S.; Horn, D.; H？wing, K.; Bernhardt, H.; Oehmke, S.; von Horsten, H.; Rebeski, D.; et al. A chemically defined production process for highly attenuated poxviruses. Biologicals 2011, 39, 50–58, doi:10.1016/j.biologicals.2010.11.005.
[67]
Graham, F.L.; Smiley, J.; Russell, W.C.; Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36, 59–74, doi:10.1099/0022-1317-36-1-59.
[68]
Fallaux, F.J.; Bout, A.; van der Velde, I.; van den Wollenberg, D.J.; Hehir, K.M.; Keegan, J.; Auger, C.; Cramer, S.J.; van Ormondt, H.; van der Eb, A.J.; et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 1998, 9, 1909–1917, doi:10.1089/hum.1998.9.13-1909.
[69]
“Designe” Cells as Substrates for the Manufacture of Viral Vaccines. Available online: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3750b1_01.htm (accessed on 27 September 2013).
[70]
Munoz, F.M.; Piedra, P.A.; Demmler, G.J. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin. Infect. Dis. 1998, 27, 1194–1200.
Berk, A.J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005, 24, 7673–7685, doi:10.1038/sj.onc.1209040.
[73]
Henry, H.; Thomas, A.; Shen, Y.; White, E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 2002, 21, 748–760, doi:10.1038/sj.onc.1205125.
[74]
Frisch, S.M. E1A as a tumor suppressor gene: Commentary re S. Madhusudan et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin. Cancer Res. 2004, 10, 2905–2907, doi:10.1158/1078-0432.CCR-04-0644.
[75]
Choi, I.-K.; Yun, C.-O. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther. 2013, 20, 70–76, doi:10.1038/cgt.2012.95.
[76]
Madhusudan, S.; Tamir, A.; Bates, N.; Flanagan, E.; Gore, M.E.; Barton, D.P.J.; Harper, P.; Seckl, M.; Thomas, H.; Lemoine, N.R.; et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin. Cancer Res. 2004, 10, 2986–2996.
Anderson, K.P.; Fennie, E.H. Adenovirus early region 1A modulation of interferon antiviral activity. J. Virol. 1987, 61, 787–795.
[79]
Leonard, G.T.; Sen, G.C. Restoration of interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein. J. Virol. 1997, 71, 5095–5101.
[80]
Unterholzner, L.; Bowie, A.G. The interplay between viruses and innate immune signaling: Recent insights and therapeutic opportunities. Biochem. Pharmacol. 2008, 75, 589–602, doi:10.1016/j.bcp.2007.07.043.
[81]
Lohr, V.; Rath, A.; Genzel, Y.; Jordan, I.; Sandig, V.; Reichl, U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 2009, 27, 4975–4982, doi:10.1016/j.vaccine.2009.05.083.
[82]
Lohr, V.; Genzel, Y.; Jordan, I.; Katinger, D.; Mahr, S.; Sandig, V.; Reichl, U. Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells. BMC Biotechnol. 2012, 12, 79.
[83]
Meiser, A.; Boulanger, D.; Sutter, G.; Krijnse Locker, J. Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release. J. Gen. Virol. 2003, 84, 1383–1392, doi:10.1099/vir.0.19016-0.
[84]
Jordan, I.; Woods, N.; Whale, G.; Sandig, V. Production of a viral-vectored vaccine candidate against tuberculosis. BioProcess Int. 2012, 10, 46–55.
[85]
Theiler, M.; Smith, H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 1937, 65, 787–800, doi:10.1084/jem.65.6.787.
[86]
Harper, J.M.; Wang, M.; Galecki, A.T.; Ro, J.; Williams, J.B.; Miller, R.A. Fibroblasts from long-lived bird species are resistant to multiple forms of stress. J. Exp. Biol. 2011, 214, 1902–1910, doi:10.1242/jeb.054643.
[87]
Wu, G.; Bazer, F.W.; Burghardt, R.C.; Johnson, G.A.; Kim, S.W.; Knabe, D.A.; Li, P.; Li, X.; McKnight, J.R.; Satterfield, M.C.; et al. Proline and hydroxyproline metabolism: Implications for animal and human nutrition. Amino Acids 2011, 40, 1053–1063, doi:10.1007/s00726-010-0715-z.
[88]
Singer, M.A. Do mammals, birds, reptiles and fish have similar nitrogen conserving systems? Com. Biochem. Physiol. B Biochem. Mol. Biol. 2003, 134, 543–558, doi:10.1016/S1096-4959(03)00027-7.
[89]
Cortin, V.; Thibault, J.; Jacob, D.; Garnier, A. High-titer adenovirus vector production in 293S cell perfusion culture. Biotechnol. Prog. 2004, 20, 858–863, doi:10.1021/bp034237l.
[90]
H？dicke, O.; Lohr, V.; Genzel, Y.; Reichl, U.; Klamt, S. Evaluating differences of metabolic performances: Statistical methods and their application to animal cell cultivations. Biotechnol. Bioeng. 2013, 110, 2633–2642, doi:10.1002/bit.24926.
[91]
Frensing, T.; Heldt, F.S.; Pflugmacher, A.; Behrendt, I.; Jordan, I.; Flockerzi, D.; Genzel, Y.; Reichl, U. Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles. PLoS One 2013, 8, e72288, doi:10.1371/journal.pone.0072288.
[92]
Frey, T.K.; Hemphill, M.L. Generation of defective-interfering particles by rubella virus in Vero cells. Virology 1988, 164, 22–29, doi:10.1016/0042-6822(88)90615-0.
[93]
Kilburn, D.G.; van Wezel, A.L. The effect of growth rate in continuous-flow cultures on the replication of rubella virus in BHK cells. J. Gen. Virol. 1970, 9, 1–7, doi:10.1099/0022-1317-9-1-1.
[94]
Jordan, I.; Horn, D.; John, K.; Sandig, V. A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium. Viruses 2013, 5, 321–339, doi:10.3390/v5010321.
[95]
Heljasvaara, R.; Rodríguez, D.; Risco, C.; Carrascosa, J.L.; Esteban, M.; Rodríguez, J.R. The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles. J. Virol. 2001, 75, 5778–5795, doi:10.1128/JVI.75.13.5778-5795.2001.
[96]
Byrd, C.M.; Bolken, T.C.; Hruby, D.E. The vaccinia virus I7L gene product is the core protein proteinase. J. Virol. 2002, 76, 8973–8976, doi:10.1128/JVI.76.17.8973-8976.2002.
[97]
Kato, S.E.M.; Strahl, A.L.; Moussatche, N.; Condit, R.C. Temperature-sensitive mutants in the vaccinia virus 4b virion structural protein assemble malformed, transcriptionally inactive intracellular mature virions. Virology 2004, 330, 127–146, doi:10.1016/j.virol.2004.08.038.
[98]
Yeh, W.W.; Moss, B.; Wolffe, E.J. The vaccinia virus A9L gene encodes a membrane protein required for an early step in virion morphogenesis. J. Virol. 2000, 74, 9701–9711, doi:10.1128/JVI.74.20.9701-9711.2000.
[99]
Harrison, S.C.; Alberts, B.; Ehrenfeld, E.; Enquist, L.; Fineberg, H.; McKnight, S.L.; Moss, B.; O’Donnell, M.; Ploegh, H.; Schmid, S.L.; et al. Discovery of antivirals against smallpox. Proc. Natl. Acad. Sci. USA 2004, 101, 11178–11192, doi:10.1073/pnas.0403600101.
[100]
Moss, B. Poxvirus cell entry: how many proteins does it take? Viruses 2012, 4, 688–707, doi:10.3390/v4050688.
[101]
Blasco, R.; Sisler, J.R.; Moss, B. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: Effect of a point mutation in the lectin homology domain of the A34R gene. J. Virol. 1993, 67, 3319–3325.
[102]
Katz, E.; Wolffe, E.; Moss, B. Identification of second-site mutations that enhance release and spread of vaccinia virus. J. Virol. 2002, 76, 11637–11644, doi:10.1128/JVI.76.22.11637-11644.2002.
[103]
Husain, M.; Weisberg, A.S.; Moss, B. Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells. Virology 2007, 366, 424–432, doi:10.1016/j.virol.2007.05.015.
[104]
McIntosh, A.A.; Smith, G.L. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J. Virol. 1996, 70, 272–281.
[105]
Ward, B.M. Visualization and characterization of the intracellular movement of vaccinia virus intracellular mature virions. J. Virol. 2005, 79, 4755–4763, doi:10.1128/JVI.79.8.4755-4763.2005.
[106]
Chakrabarti, S.; Sisler, J.R.; Moss, B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 1997, 23, 1094–1097.
[107]
Gallego-Gómez, J.C.; Risco, C.; Rodríguez, D.; Cabezas, P.; Guerra, S.; Carrascosa, J.L.; Esteban, M. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J. Virol. 2003, 77, 10606–10622, doi:10.1128/JVI.77.19.10606-10622.2003.
[108]
Sancho, M.C.; Schleich, S.; Griffiths, G.; Krijnse-Locker, J. The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis. J. Virol. 2002, 76, 8318–8334, doi:10.1128/JVI.76.16.8318-8334.2002.
[109]
Wolff, M.W.; Siewert, C.; Lehmann, S.; Hansen, S.P.; Djurup, R.; Faber, R.; Reichl, U. Capturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers. Biotechnol. Bioeng. 2010, 105, 761–769.
[110]
Wolff, M.W.; Siewert, C.; Hansen, S.P.; Faber, R.; Reichl, U. Purification of cell culture-derived modified Vaccinia Ankara virus by pseudo-affinity membrane adsorbers and hydrophobic interaction chromatography. Biotechnol. Bioeng. 2010, 107, 312–320, doi:10.1002/bit.22797.
